富科伊丹通过调节微生物群-肠-大脑轴来改善小鼠中罗诺诱导的帕金森症
Xiaojing Yang1, Xuan Zhang1, Yufang Ma1
1National-Local Joint Engineering Research Center for Drug-Research and Development (R & D) of Neurodegenerative Diseases, Dalian Medical University, Dalian 116044, China.
International journal of biological macromolecules
|November 9, 2024
概括
富科伊丹治疗通过减少炎症和多巴胺神经元损伤来缓解帕金森病的症状. 这种神经保护与肠道微生物群-大脑轴有关,这表明富科伊丹是帕金森病的潜在治疗剂.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 微生物群-肠-大脑轴在帕金森病 (PD) 发病过程中起着至关重要的作用.
- 富科伊丹通过减轻PD模型中的氧化应激而表现出神经保护作用.
- 微生物群-肠-大脑轴在福科丹神经保护活性中的具体参与仍然不清楚.
研究的目的:
- 为了研究福科伊丹对罗 (ROT) 诱导的小鼠帕金森病 (PD) 的治疗效果.
- 阐明微生物群-肠-大脑轴在福柯丹神经保护机制中的参与.
主要方法:
- 在小鼠中使用罗特 (ROT) 诱导PD.
- 通过食给予富可伊丹.
- 评估神经炎症,多巴胺神经元损伤,运动功能,肠道健康和肠道屏障完整性.
- 对肠道微生物群组成的分析.
- 便微生物群移植 (FMT) 和益生菌补充剂 (Lactobacillus murinus).
- 对LPS/TLR4/NF-κB信号通路的研究.
主要成果:
- 在ROT诱导的PD小鼠中,富科伊丹治疗减轻了神经炎症,多巴胺神经元损伤和运动功能障碍.
- 富科伊丹改善了肠道功能障碍,肠道炎症和肠道屏障破坏.
- 富科伊丹改变了肠道微生物群的组成,减少了阿克尔曼西亚尼菲拉和Lactobacillus johnsonii,同时增加了Lactobacillus murinus.
- 接受富可伊丹治疗的小鼠的FMT和Lactobacillus murinus补充剂模仿了富可伊丹的治疗效果.
- 这些影响与LPS/TLR4/NF-κB信号通路的下调有关.
结论:
- 富科伊丹通过调节微生物群-肠-大脑轴来证明帕金森病的治疗潜力.
- 富科伊丹的神经保护作用包括减少炎症和多巴胺神经元损伤,可能通过肠道微生物群调节.
- 富科伊丹可能是未来帕金森病治疗的有希望的候选人.
相关概念视频
Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482


